• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2012 Product Image

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2012

  • ID: 2244961
  • September 2012
  • 52 pages
  • Global Markets Direct

Peripheral Neuropathy (Sensory Neuropathy) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peripheral Neuropathy (Sensory Neuropathy). Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for READ MORE >

2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Peripheral Neuropathy (Sensory Neuropathy) Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) 8
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics under Development by Companies 10
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics – Products under Development by Companies 16
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Peripheral Neuropathy (Sensory Neuropathy) Therapeutics Development 18
NsGene A/S 18
Neuren Pharmaceuticals Limited 19
NeurogesX, Inc. 20
Allon Therapeutics Inc. 21
Peripheral Neuropathy (Sensory Neuropathy) – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
capsaicin - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
AL-309 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
NNZ-2591 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NsG-31 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
amifostine - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Amitriptyline + Ketamine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
glutamine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Carboplatin + Glutathione + Paclitaxel - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
thioctic acid [JAN] - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Immunoglobulin - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
flupirtine maleate - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics – Drug Profile Updates 41
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics – Discontinued Products 43
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics - Dormant Products 44
Peripheral Neuropathy (Sensory Neuropathy) – Product Development Milestones 45
Featured News & Press Releases 45
Nov 17, 2011: Pfizer Obtains European Approval For Vyndaqel For Transthyretin Familial Amyloid Polyneuropathy 45
Feb 09, 2011: CeNeRx Receives FDA IND Approval For CXB909 46
Feb 07, 2011: EpiCept Reports Positive Results From EpiCept NP-1 Trial In Patients With Chemotherapy-Induced Peripheral Neuropathy 47
Sep 08, 2010: DARA Announces Phase III Trial Results Of KRN5500 In Patients With Chemotherapy Induced Peripheral Neuropathy And Advanced Cancer 48
Jun 11, 2010: Pfizer, Eisai to launch postherpetic neuralgia drug Lyrica Capsules on June 22 48
Jun 11, 2010: Pfizer, Eisai to launch postherpetic neuralgia drug Lyrica Capsules on June 22 48
May 28, 2010: Relevare Pharmaceuticals Presents Latest Clinical Trial Data On CNSB015 At Third International Congress On Neuropathic Pain In Athens, Greece 49
Apr 06, 2010: Pfizer told to Pay $142.1 million for Neurontin marketing violations. 49
Dec 20, 2009: CNSBio Inc. To Present Latest Clinical Trial Data For CNSB015 At Neuropathic Pain Conference in San Francisco 50
Nov 18, 2009: NeoPharm Presents LE-DT Phase I Data At The AACR Conference 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Tables
Number of Products Under Development for Peripheral Neuropathy (Sensory Neuropathy), H2 2012 8
Products under Development for Peripheral Neuropathy (Sensory Neuropathy) – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
NsGene A/S, H2 2012 18
Neuren Pharmaceuticals Limited, H2 2012 19
NeurogesX, Inc., H2 2012 20
Allon Therapeutics Inc., H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 27
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics – Drug Profile Updates 41
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics – Discontinued Products 43
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics – Dormant Products 44

List of Figures
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H2 2012 8
Products under Development for Peripheral Neuropathy (Sensory Neuropathy) – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Discovery and Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Route of Administration, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Molecule Type, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 27

Question What companies/institutes are mentioned in this product?
Answer The product provides "Number of Products under Development by Companies, H2 2012" for:

- Allon Therapeutics Inc.
- Neuren Pharmaceuticals Limited
- NeurogesX, Inc.
- NsGene A/S
- Relevare Pharmaceuticals Ltd.

as well as "Number of Products under Investigation by Universities/Institutes, H2 2012" for:

- Aarhus University
- North Central Cancer Treatment Group
- Oregon Health and Science University
- The University of Texas M. D. Anderson Cancer Center
- University of Rochester
- Weill Cornell Medical College
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos